


TRXA BRIDGe Awards – Capturing Measures of Success

mdrew@c-path.org



TRXA BRIDGe Awards for Drug Discovery





TRxA is a **global** drug discovery and development program that supports **academic scientists** in advancing new, **small-molecule therapeutics** from the lab to the clinic.

BRIDGe Awards:

- Stage 1: US \$250,000
- Stage 2: US \$500,000
- Stage 3: US \$1,000,000

Therapeutic area agnostic

Measures of Success



What:

- IND submitted, drug in the clinic, drug approval aspirational, long game
- Licensing events validation of technology
- Follow-on funding reliance on PI to disseminate
- Patents, publications and citations easy to measure

How:

- Project team reporting, NIH funding through RePORTER
- SciFinder (publications, citations etc.)
- PatSnap (Intellectual Property, file wrapper actions, IP citations)

CAS SciFinderⁿ (not meant to be a sales pitch)




- CAplus contains journal articles, patents, books, clinical trials, preprints, editorials....
- 47 million records from more than 180 countries
- Indexes >50,000 journals
- Article records are added to SciFinder within 7 days of publication
- Patent citations from 9 patent offices worldwide
- Patent records are added 2 days after publication
- CAplus records begin in 1907 and continue to the present, but there are also more than 224,000 patent and article records dating back to 1808



CAS SciFinderⁿ





- PI and project team members (author or citation)
- Markush search around chemical matter
- Automated search provides email results on desired frequency

Pros

Comprehensive (patents and pubs)
Widely used in academia and industry
Boolean operators
Ability to analyze search results
Extensive training available

Cons

Expensive license

Takes refinement to limit results

Steep learning curve

Boolean operators not intuitive

No specific publication-type filter



Advancing Drug Development. Improving Lives. Together.

Please connect with TRxA@c-path.org for follow up conversations **c-path.org**